Table 2.
The top ten results of KEGG enrichment analysis.
| ID | Description | p value | p adjust | q value | |
|---|---|---|---|---|---|
| KEGG | hsa05215 | Prostate cancer | 2.22E−09 | 2.24E−07 | 8.21E−08 |
| KEGG | hsa05415 | Diabetic cardiomyopathy | 2.56E−09 | 2.24E−07 | 8.21E−08 |
| KEGG | hsa05417 | Lipid and atherosclerosis | 4.46E−09 | 2.30E−07 | 8.45E−08 |
| KEGG | hsa04931 | Insulin resistance | 5.27E−09 | 2.30E−07 | 8.45E−08 |
| KEGG | hsa01522 | Endocrine resistance | 6.96E−08 | 2.44E−06 | 8.94E−07 |
| KEGG | hsa05142 | Chagas disease | 9.20E−08 | 2.68E−06 | 9.84E−07 |
| KEGG | hsa04917 | Prolactin signaling pathway | 2.25E−07 | 5.62E−06 | 2.06E−06 |
| KEGG | hsa04926 | Relaxin signaling pathway | 4.63E−07 | 1.01E−05 | 3.72E−06 |
| KEGG | hsa05418 | Fluid shear stress and atherosclerosis | 7.70E−07 | 1.37E−05 | 5.02E−06 |
| KEGG | hsa05205 | Proteoglycans in cancer | 7.82E−07 | 1.37E−05 | 5.02E−06 |